Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.
Looking for leads, investment insights, or competitive intelligence?
News about Pfizer
It announced that it will shut down its research efforts around neurological disorders.
The company says it expects 300 job cuts.
The FDA approved 46 novel drugs in 2017 versus 22 in 2016.
Ringaskiddy residents say they have an extra spring in their step.
Insights from our annual roundtable on the best stocks and the biggest risks.